This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:celiac [02.17.2019] – [Celiac disease] sallieq | home:diseases:celiac [07.19.2019] – [Celiac disease] sallieq | ||
---|---|---|---|
Line 5: | Line 5: | ||
====== Celiac disease ====== | ====== Celiac disease ====== | ||
- | < | + | < |
Line 64: | Line 64: | ||
(({{pubmed> | (({{pubmed> | ||
- | {{tag> | + | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. |
+ | |||
+ | In 2015 I read that 6 individuals in the USA are currently suing maker of Benicar. Somewhere I saw that 1.9 million individuals are currently taking Olmesartan Medoxomil. | ||
+ | |||
+ | 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | ||
+ | (({{pubmed> | ||
+ | |||
+ | {{tag> | ||